For the first time, the present study elucidates the therapeutic potential of a novel mAb5E6 directed towards a unique epitope on surface retained functionally relevant MUC16-Cter domain in preclinical models of PC and NSCLC and differentiates it from other available MUC16 targeting antibodies20,23,31,42. This evidence concerns the gene MUC16 and pachyonychia congenita.